The Latest Cardiac and Vascular News
System includes mechanical and aspiration thrombectomy devices to treat peripheral vascular disease ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that Innova Vascular, Inc. (Innova) has submitted a […]
Fiscal Year 2023 Second Quarter Highlights Net sales of $85.4 million increased 9.1% compared to the prior-year quarter Med Tech net sales of $24.5 million increased 29.7% Med Device net sales of $60.9 million increased 2.6% Gross margin of 52.8% increased 100 basis points year over year GAAP loss per […]
-RBT-1 met the primary biomarker endpoint as well as several key clinical endpoints; positive data supports the potential for RBT-1 to improve postoperative outcomes in cardiothoracic surgery- –RBT-1 treatment demonstrated a reduction in time on ventilator, ICU days, length of hospital stay and 30-day hospital readmission rates- –Planned pivotal Phase […]
WEST CHESTER, Pa., Jan. 5, 2023 /PRNewswire/ — VESTECK, Inc. is proud to announce that another global Endovascular thought leader, Professor Michel Reijnen has agreed to join the VESTECK Scientific Advisory Board. When asked about the patient benefits of the VESTECK, “SUTURE-TIGHT”™ catheter technology, Professor Reijnen said, “After >25 years of performing EVAR procedures we are […]
IRVINE, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced that it has appointed Dan Dearen, medical device industry executive, to its Board of Directors. Mr. Dearen has over 35 years of experience in the medical […]
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 30, 2022 it granted stock options to purchase an aggregate of 130,000 shares of common stock to 6 new employees, whose employment commenced in December 2022, as a material inducement to […]
Bellerophon to receive a license payment of $6 million, as well as royalties on net sales in Greater China WARREN, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that […]
NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) — LEXEO Therapeutics, Inc. (LEXEO), a clinical-stage biotech company advancing a pipeline of adeno-associated virus (AAV)-based gene therapy candidates for cardiovascular and central nervous system (CNS) diseases, today announced the expansion of its leadership team, with the appointment of Micah Zajic as Chief Financial […]
– Topline results from ENLIVEN Phase 2b NASH trial on track for first quarter of 2023 – – Feedback from FDA supports advancement of Phase 3 program for pegozafermin in SHTG; plan to initiate first of two SHTG Phase 3 trials in the first half of 2023 – – Secured $100 […]
Leading Medical Practice in Idaho Will be the First Functional Medicine Clinic to Offer the Epi+Gen CHD Precision Cardiovascular Test CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings Inc (Nasdaq: CDIO), a leading precision cardiovascular diagnostics company, and Healing Sanctuary Clinic, a leading medical practice serving health-forward consumers in Idaho, today announced the availability of […]
